These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 1879298

  • 1. [Inhibitory effect of monoclonal antibody PD4 on Ha-ras transformed cells Rat3-3].
    Yin WN.
    Zhonghua Zhong Liu Za Zhi; 1991 Mar; 13(2):82-6. PubMed ID: 1879298
    [Abstract] [Full Text] [Related]

  • 2. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
    Ciardiello F, McGeady ML, Kim N, Basolo F, Hynes N, Langton BC, Yokozaki H, Saeki T, Elliott JW, Masui H.
    Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
    [Abstract] [Full Text] [Related]

  • 3. The antisense c-Ha-ras oligodeoxynucleotides inhibit the proliferation of the gastrocarcinoma-DNA-transformed rat 3-3 cells and reduce the p21 expression of the cells.
    Xu Y, Deng GR, Liang YY, Li C.
    Sci China B; 1991 Jan; 34(1):35-41. PubMed ID: 2015062
    [Abstract] [Full Text] [Related]

  • 4. Inhibited neoplastic phenotype by the c-Ha-ras antisense RNA.
    Lu GR, Wu CJ, Ke Y, Xiong X, Li YJ, Liu JM, Xu Y, Xu W, Li JY, Deng GR.
    Sci China B; 1991 Dec; 34(12):1485-91. PubMed ID: 1801843
    [Abstract] [Full Text] [Related]

  • 5. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
    Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM, Wickstrom E.
    Cancer Res; 1993 Feb 01; 53(3):577-80. PubMed ID: 8425190
    [Abstract] [Full Text] [Related]

  • 6. [Inhibition of antisense DNA and its derivative on gastric transformed cell carcinogenicity].
    Yang D, Li T, Xu W.
    Zhonghua Wai Ke Za Zhi; 1995 Jan 01; 33(1):26-8. PubMed ID: 7774440
    [Abstract] [Full Text] [Related]

  • 7. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J, Jiang B, Coffey RJ, Barnard J.
    Mol Cancer Res; 2004 Apr 01; 2(4):233-41. PubMed ID: 15140945
    [Abstract] [Full Text] [Related]

  • 8. Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo.
    Hamilton M, Wolfman A.
    Oncogene; 1998 Mar 01; 16(11):1417-28. PubMed ID: 9525741
    [Abstract] [Full Text] [Related]

  • 9. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
    Su ZZ, Austin VN, Zimmer SG, Fisher PB.
    Oncogene; 1993 May 01; 8(5):1211-9. PubMed ID: 8479744
    [Abstract] [Full Text] [Related]

  • 10. ras-induced neoplastic transformation and sensitivity to tumor necrosis factor.
    Fernandez A, Chen PW, Ananthaswamy HN.
    Anticancer Res; 1994 May 01; 14(6B):2649-52. PubMed ID: 7872696
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras.
    Kawada M, Fukazawa H, Mizuno S, Uehara Y.
    Biochem Biophys Res Commun; 1997 Feb 24; 231(3):735-7. PubMed ID: 9070883
    [Abstract] [Full Text] [Related]

  • 12. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells.
    Daaka Y, Wickstrom E.
    Oncogene Res; 1990 Feb 24; 5(4):267-75. PubMed ID: 2204019
    [Abstract] [Full Text] [Related]

  • 13. Human retinoblastoma gene product prevents c-Ha-ras oncogene mediated cellular transformation of mouse fibroblasts.
    Kivinen L, Pitkänen K, Laiho M.
    Oncogene; 1993 Oct 24; 8(10):2703-11. PubMed ID: 8378082
    [Abstract] [Full Text] [Related]

  • 14. Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells.
    Wang XY, Repasky E, Liu HT.
    Exp Cell Res; 1999 Jul 10; 250(1):253-63. PubMed ID: 10388539
    [Abstract] [Full Text] [Related]

  • 15. Transforming and oncogenic potential of activated c-Ha-ras in three immortalized human breast epithelial cell lines.
    Wang B, Soule HD, Miller FR.
    Anticancer Res; 1997 Jul 10; 17(6D):4387-94. PubMed ID: 9494538
    [Abstract] [Full Text] [Related]

  • 16. Immune response to progressor variants derived from transfection of an ultraviolet radiation-induced C3H mouse regressor tumor cell line with activated Harvey-ras oncogene.
    Kaba DS, Pierceall WE, Price JE, Ananthaswamy HN.
    Cancer Res; 1990 Jun 01; 50(11):3159-66. PubMed ID: 2185882
    [Abstract] [Full Text] [Related]

  • 17. Induction of the neoplastic phenotype of EBV-established B lymphocytes by the human Ha-ras oncogene.
    Nasi S, Sirinian MI, Panetta G, Marchetti A, Jucker R.
    Oncogene; 1990 Jan 01; 5(1):117-22. PubMed ID: 2157177
    [Abstract] [Full Text] [Related]

  • 18. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
    Kuo ML, Chou YW, Chau YP, Huang TS.
    Mol Carcinog; 1997 Apr 01; 18(4):221-31. PubMed ID: 9142217
    [Abstract] [Full Text] [Related]

  • 19. p21ras independent down-regulation of ras-induced increases in natural antibody binding during tumor progression.
    Tough DF, Feng X, Chow DA.
    Nat Immun; 1995 Apr 01; 14(1):20-34. PubMed ID: 7599459
    [Abstract] [Full Text] [Related]

  • 20. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA, Link VC, Greene MI.
    Oncogene; 1988 Apr 01; 2(4):387-94. PubMed ID: 2896329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.